Australia's most trusted
source of pharma news
Wednesday, 12 March 2025
Posted 11 March 2025 AM
The success of Brukinsa sees BeiGene at an inflection point, and the pharma plans to leap at the 'once-in-a-lifetime' opportunity the blockbuster provides.
BeiGene saw net product revenue grow 73 per cent year-on-year to $6.07 billion (US$3.780 billion) in 2024, mostly on the back of BTK inhibitor Brukinsa, which saw global sales increase 105 per cent over that time to hit $4.24 billion (US$2.644 billion) for 2024.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.